Presenter Dr. Maya Mueller-Wolf, from the German Cancer Research Center in Heidelberg, and colleagues included 30 patients with biopsy-proven, low-risk prostate cancer in a phase I clinical study. Mueller-Wolf's group performed the technique using Profound Medical's PAD-105 prostate ablation device, in conjunction with a 3-tesla MR scanner from Siemens Healthcare.
The team confirmed that cancer cells were destroyed using contrast-enhanced MR immediately after the procedure and at the 12-month follow-up. Median treatment time and prostate volume were 36 minutes and 44 mL, respectively.
The procedure was well-tolerated by all patients, and there were no intraoperative complications, according to the researchers. They further confirmed that the treatment was successful with a median prostate-specific antigen (PSA) decrease from 5.8 ng/mL to 0.7 ng/mL at one month after the procedure in 24 patients.
Whole-gland ablation can be safely and accurately performed using the technology, the group concluded.
